stonks4u
Sign up free
MIST logo

MIST Milestone Pharmaceuticals Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$1.10
+0.03 (+2.80%)

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United…

Market Cap: $136.95Mwww.milestonepharma.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

105
105
Aug 12Aug 12

Quote

Day Range
$1.04 – $1.10
52-Week Range
$1.00 – $3.06
Volume
$2.12M
Market Cap
$136.95M
50-Day Avg
$1.23
200-Day Avg
$1.72
Prev Close
$1.07
Open
$1.05

Valuation & Ratios

P/E Ratio
-2.69
EPS
$-0.75
P/B Ratio
4.06
P/S Ratio
109.60
Debt/Equity
1.40
Current Ratio
8.01
Dividend Yield
+0.0%
Gross Margin
+92.6%

Returns & Efficiency

Return on Equity
-151.0%
Return on Assets
-55.5%
FCF Yield
-29.1%
EV/EBITDA
-2.60

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$1.55M$-63.06M$-0.75
2024$0.00$-41.52M$-0.67
2023$1.00M$-59.69M$-1.39
2022$5.00M$-58.39M$-1.35
2021$15.00M$-42.85M$-1.02

Social Signal Score

57
5d
57
4 mentions
—
30d
56
4 mentions
—
60d
56
4 mentions
—
90d
56
4 mentions
—
news: 4

Earnings

Tue, Nov 17(in 3 months)

Consensus estimate $-0.21 per share

2of 7 quarters beat consensus

Typical surprise -11.1% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 12$-0.21 vs $-0.20miss
  • Wed, May 13$-0.20 vs $0.06miss
  • Fri, Mar 20$-0.16 vs $-0.18beat
  • Wed, Nov 12$-0.12 vs $-0.17beat
  • Tue, Aug 12$-0.20 vs $-0.18miss
  • Wed, May 14$-0.31 vs $-0.19miss

Estimates and results for MIST via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

MISThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (4)

  • Newsseekingalpha.com·2d ago·Positive

    Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsmarketbeat.com·3d ago·Positive

    Milestone Pharmaceuticals Q2 Earnings Call Highlights Milestone Pharmaceuticals NASDAQ: MIST reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, or AFib-RVR.

    View source ↗
  • Newszacks.com·3d ago·Negative

    Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.

    View source ↗
  • Newsglobenewswire.com·3d ago·Neutral

    Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray

    View source ↗